Drug intelligence / Profile preview

dupilumab + guselkumab

Development stage: Preclinical
Lead developer: Janssen Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Combination therapy of two monoclonal antibodies used to treat patients with concurrent inflammatory skin conditions. Dupilumab is an IL-4 receptor alpha antagonist that blocks IL-4 and IL-13 signaling, while guselkumab selectively binds to the p19 subunit of IL-23. This combination targets different inflammatory pathways simultaneously and has shown efficacy in treating patients with both psoriasis and atopic dermatitis or other related conditions.

Targets

IL4R (Interleukin-4 receptor alpha subunit)IL23A (Interleukin-23 p19 Subunit)

Beyond the preview

Go deeper on dupilumab + guselkumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dupilumab + guselkumab.

Explore the full profile